Increased glucosylceramide production leads to decreased cell energy metabolism and lowered tumor marker expression in non-cancerous liver cells

Marthe-Susanna Wegner1,2 · Nina Schömel1 · Ellen M. Olzomer2 · Sandra Trautmann1 · Catherine Olesch3 · Frances L. Byrne2 · Bernhard Brüne3 · Robert Gurke1,4 · Nerea Ferreirós1 · Andreas Weigert2 · Gerd Geisslinger1,4 · Kyle L. Hoehn2

Received: 21 April 2021 / Revised: 15 September 2021 / Accepted: 29 September 2021 / Published online: 9 October 2021 © The Author(s) 2021

Abstract
Hepatocellular carcinoma (HCC) is one of the most difficult cancer types to treat. Liver cancer is often diagnosed at late stages and therapeutic treatment is frequently accompanied by development of multidrug resistance. This leads to poor outcomes for cancer patients. Understanding the fundamental molecular mechanisms leading to liver cancer development is crucial for developing new therapeutic approaches, which are more efficient in treating cancer. Mice with a liver specific UDP-glucose ceramide glucosyltransferase (UGCG) knockout (KO) show delayed diethylnitrosamine (DEN)-induced liver tumor growth. Accordingly, the rationale for our study was to determine whether UGCG overexpression is sufficient to drive cancer phenotypes in liver cells. We investigated the effect of UGCG overexpression (OE) on normal murine liver (NMuLi) cells. Increased UGCG expression results in decreased mitochondrial respiration and glycolysis, which is reversible by treatment with EtDO-P4, an UGCG inhibitor. Furthermore, tumor markers such as FGF21 and EPCAM are lowered following UGCG OE, which could be related to glucosylceramide (GlcCer) and lactosylceramide (LacCer) accumulation in glycosphingolipid-enriched microdomains (GEMs) and subsequently altered signaling protein phosphorylation. These cellular processes lead to decreased proliferation in NMuLi/UGCG OE cells. Our data show that increased UGCG expression itself does not induce pro-cancerous processes in normal liver cells, which indicates that increased GlcCer expression leads to different outcomes in different cancer types.
Introduction

The most frequent type of primary liver cancer is hepatocellular carcinoma (HCC), which is characterized by transformation of liver cells into tumor cells. Only 30% of HCC patients are suitable for liver resection or transplantation leading to a high death rate for the patients. In addition, development of multidrug resistance during pharmacotherapy is common in HCC patients [42]. In recent years, progress has been made regarding pharmacologic treatment of HCC. The multikinase inhibitor sorafenib is a first-line therapy for advanced HCC (reviewed in [13]). Unfortunately, sorafenib is effective only in the minority of HCC patients and increases life span only by roughly 12 weeks [2, 25]. In 2018, lenvatinib (also a multikinase inhibitor) was approved from the Food and Drug Administration (FDA) as a first-line treatment of patients with unresectable HCC (reviewed in [13]). Unfortunately, sorafenib is effective only in the minority of HCC patients and increases life span only by roughly 12 weeks [2, 25]. In 2018, lenvatinib (also a multikinase inhibitor) was approved from the Food and Drug Administration (FDA) as a first-line treatment of patients with unresectable HCC (reviewed in [13]). Despite exhibiting a higher response rate of lenvatinib over sorafenib the REFLECT trial showed no inferiority of one of the drugs (reviewed in [32]). On May 29, 2020, the FDA approved programmed cell death protein 1 (PD1)/programmed cell death 1 ligand 1 (PD-L1) immune checkpoint inhibitor atezolizumab in combination with angiogenesis growth factor (VEGF) inhibitor bevacizumab for patients with unresectable or metastatic HCC without prior systemic therapy. Combination therapy with atezolizumab and bevacizumab provides superior outcome for the patients compared with sorafenib, but the incidence of serious adverse events is increased (reviewed in [32]). Despite these novel therapeutic approaches, for many of the HCC patients only palliative care applies. This reveals the importance of investigating the molecular mechanisms of HCC development. Furthermore, understanding these basic mechanisms contributes to development of new therapeutic strategies for prevention and treatment of HCC. UDP-glucose ceramide glucosyltransferase (UGCG) gene expression is altered in 0.8% of HCC patients (TCGA, Firehose Legacy) [9, 14]. UGCG overexpression is linked to multidrug resistance development in cancer cells (reviewed in [45]), which is ascribed to the unique ability of UGCG to transfer UDP-glucose to ceramide, which results in de novo synthesis of glucosylceramide (GlcCer, cerebroside). Since GlcCer is the precursor for all complex glycosphingolipids (GSLs), UGCG is the key enzyme of GSL metabolism. Synthesized in the Golgi apparatus, GSLs are essential for cellular survival. They are also involved in signal transmission processes. By adding a galactose molecule to GlcCer,
lactosylceramide (LacCer, globoside) is produced. The more complex GSLs globosides (e.g. globotriaosylceramide (Gb3)) and gangliosides (e.g. monosialodihexosylganglioside (GM3)) are synthesized by adding monosaccharides to LacCer (reviewed in [16]).

The lysosomal storage disease Morbus Gaucher is characterized by a mutation of the glucocerebrosidase (GBA) gene, which results in GlcCer accumulation. Morbus Gaucher patients exhibit hypermetabolism [11]. In addition, these patients show an increased risk for liver cancer [33]. Hence, it is interesting to identify the role of GlcCer in liver cell metabolism and whether GlcCer contributes to the pathology of liver tumors.

Currently, only two studies show the involvement of UGCG in the molecular processes of HCC. Jennemann et al. showed increased UGCG expression in HCC tissue compared to non-cancerous tissue [21]. Diethylaminoethylamine (DEN)-induced liver tumors in mice, which exhibit a liver specific UGCG knockout (KO), show delayed tumor growth. This is ascribable to decelerated cytokinesis, whereas, the authors do not mention which signaling pathway is involved in the described effects. Furthermore, the ganglioside GM2 is hardly detectable, whereas, the sphingomyelin concentration is increased. Possibly, this is a cellular mechanism to avoid ceramide induced apoptosis [21]. This study was unable to show that a lack of GSLs protects from liver tumor development, which implicates that beside UGCG, other proteins/pathways play a role in HCC development. The second study was also carried out with liver cancer cells and showed sorafenib induced UGCG expression resulting in sorafenib resistance [40]. Following UGCG inhibition, no alterations of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase 1 (ERK) signaling could be detected in liver cancer cells [33]. One reason for this could be that tumor cells were used in these studies in which the described signaling pathways are rather induced in the onset of carcinogenesis.

To investigate early onset of UDP-glucose ceramide glucoyltransferase (UGCG)-mediated pro-cancerous changes in normal liver cells, we overexpressed UGCG in NMuLi cells, analyzed several key cellular processes and measured the expression of tumor markers. Following UGCG overexpression (OE), NMuLi cells show decreased mitochondrial respiration and glycolysis accompanied by increased mitochondrial superoxide levels and decreased tumor marker expression (graphical abstract). We also detected increased dihydroceramide (dhCer) levels in endoplasmic reticulum (ER)/mitochondria fractions in NMuLi/UGCG OE cells. Furthermore, altered signaling of glycogen synthase kinase 3 β (GSK3β), adenosine monophosphate (AMP)-activated protein kinase (AMPKα) and 3′-phosphoinositide-dependent kinase 1 (PDK1) was detected, presumably based on glucosylceramide (GlcCer) and lactosylceramide (LacCer) accumulation in glycosphingolipid-enriched microdomains (GEMs) resulting in decreased cell proliferation.

**Results**

**UGCG OE verification**

We performed lentiviral transduction to overexpress UDP-glucose ceramide glucosyltransferase (UGCG) in non-cancerous murine liver cells (NMuLi/UGCG OE cells). Overexpression (OE) of UGCG is confirmed via mRNA (Fig. 1A) and protein (Fig. 1B, S1A) level analysis compared to control cells (NMuLi/EV-2 cells).

**UGCG OE decreases glycolysis and OXPHOS**

First we investigated the effect of an UGCG OE on liver cell metabolism. Basal mitochondrial respiration is significantly decreased in NMuLi/UGCG OE cells compared to control cells (Fig. 1C, S1B). Adenosine triphosphate (ATP) production (basal respiration —respiration after oligomycin injection) and maximal respiration rate (respiration after antimycin a/rotenone injection) are also significantly decreased in NMuLi/UGCG OE cells compared to control cells (Fig. 1C, S1B). No statistically significant differences of mitochondrial oxidative phosphorylation (OXPHOS) complex protein concentrations between NMuLi/UGCG OE and control cells have been detected (Fig. 1D, S1C). However, ATP levels are decreased in UGCG overexpressing cells (Fig. 1E). Furthermore, the basal glycolytic rate (basal extracellular acidification rate (ECAR)) is lower in NMuLi/UGCG OE cells (Fig. 1F, S1D). Interestingly, glycolytic capacity is not significantly changed between the cells (Fig. 1F). The energy map shows that following UGCG OE, NMuLi cells transform from an energetic to a glycolytic/quiescence state (Fig. 1G).

We analyzed glycolytic (J_{ATP\text{gly}}) and oxidative ATP (J_{ATP\text{ox}}) production rates from raw extracellular acidification and respiration data, which confirm the metabolic shift to a glycolytic/quiescence state following UGCG OE (S1E). NMuLi/UGCG knockdown (KD) cell data (verified KD in S1F) confirm these findings by showing increased basal respiration, ATP production, maximal respiration (S1G) and glycolytic capacity in NMuLi/UGCG KD cells (S1H) compared to control cells. Lowered glycolysis in NMuLi/UGCG OE cells is also shown by decreased evolved $^{3}\text{H}_{2}\text{O}$ concentration following supplementing $3\text{H}$-D-glucose to the media (Fig. 2A). Decreased oxidative metabolism is verified by substrate competition assay data with [U-$^{14}$C]-labeled glucose, [L-$^{14}$C(U)]-labeled...
glutamine and [1-14C(U)]-labeled palmitate (Fig. 2B). OE of UGCG lowers levels of captured 14CO2, which demonstrates that UGCG OE decreases substrate oxidation in NMuLi cells (Fig. 2B). Interestingly, basal respiration in NMuLi/UGCG OE cells can be rescued by treatment with 0.5 μM EtDO-P4, an UGCG inhibitor, whereas, no EtDO-P4 effect on basal respiration in control cells was detected (Fig. 2C). ATP production of NMuLi/UGCG OE cells is 0.4-fold increased following treatment with EtDO-P4, whereas, ATP production in NMuLi/EV-2 cells is lowered (Fig. 2C). EtDO-P4 also improves maximal respiration of NMuLi/EV-2 cells, but to a smaller extent when compared to NMuLi/UGCG OE cells (Fig. 2C). Furthermore, basal ECAR is 0.25-fold higher in NMuLi/EV-2 cells and 0.5-fold higher in NMuLi/UGCG OE cells following EtDO-P4 stimulation (Fig. 2D). Glycolytic capacity is improved in NMuLi/UGCG OE cells by 0.5 μM EtDO-P4 stimulation, whereas, in control cells EtDO-P4 leads to lowered glycolytic capacity (Fig. 2D). The data are in line with KD data, since EtDO-P4 has no effect on the OCR and ECAR in NMuLi/UGCG KD cells (S1H).

**UGCG does not affect mitochondrial mass, but mitochondrial ROS levels**

To exclude the possibility that UGCG-dependent effects on cell metabolism are related to changed mitochondrial
Increased glucosylceramide production leads to decreased cell energy metabolism and lowered mass, we determined the number of mitochondrial DNA (mtDNA) copies. No statistically significant differences between the mtDNA in NMuLi/UGCG OE and control cells were detected (Fig. 3A). In addition, we used the fluorescent mitochondrial dye nonyl acridine orange (NAO) for mitochondrial mass analysis. Following cell labeling with NAO, we analyzed vital mitochondria by flow cytometry. No significant differences between NMuLi/UGCG OE and control cells were detected (Fig. 3B). Since mitochondrial respiration is clearly UGCG-dependently regulated, we determined mitochondrial superoxide in NMuLi cells. Mitochondrial superoxide increases in NMuLi cells in an UGCG-dependent manner when compared to the control (Fig. 3C), whereas, the total reactive oxygen species (ROS) level is unchanged (Fig. 3D). No significant changes in nicotinamide adenine dinucleotide (NAD)+, NAD+ hydrogen (NADH) concentrations (S2A) and antioxidant capacity (S2B) between NMuLi/UGCG OE and control cells were detected. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay data show increased viability of NMuLi/UGCG OE cells following 25 μM d,l-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), an UGCG inhibitor, treatment compared to mock control of NMuLi/EV-2 cells (Fig. 3E). In summary, UGCG-dependent effects on cell metabolism are not related to mitochondrial mass change, mitochondrial superoxide is increased

Fig. 2 Glycolysis and substrate oxidation in NMuLi cells and oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) following EtDO-P4 treatment of NMuLi/UGCG OE and control cells. A Using 3-3H-D-glucose and subsequently measuring released labeled H2O, anaerobic glycolysis was determined. Data are normalized to protein concentration and presented as mean of n = 3 ± SEM. Unpaired t test with Welch’s correction. B Substrate oxidation was analyzed by evolved 14CO2 following U-14C-glucose, L-14C-glutamine, and 1-14C-palmitate treatment. Data are normalized to protein concentration and presented as mean of n = 3 ± SEM. Unpaired t test with Welch’s correction. C Oxygen consumption rate (OCR) following EtDO-P4 treatment determined by Seahorse XFe analyzer. ATP production (basal respiration—respiration after oligomycin injection) and maximal respiration rate (respiration after N5,N6-bis(2-fluorophenyl)-1,2,5-oxadiazolo[3,4-b]pyrazine-5,6-diamine (BAM15) injection—respiration after antimycin a/rotenone injection). Data are presented as mean of n = 3 ± SEM. Tukey’s multiple comparisons test. D Extracellular acidification rate (ECAR) following EtDO-P4 treatment quantified by Seahorse XFe analyzer. Glycolytic capacity is deduced from ECAR after oligomycin treatment—basal ECAR. Data are presented as mean of n = 3 ± SEM. Tukey’s multiple comparisons test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001
following UGCG OE and NMuLi/UGCG OE cell viability is increased by inhibiting UGCG.

UGCG-derived glycosphingolipids change sphingolipid composition of ER/mitochondria fractions

Endoplasmic reticulum (ER) and mitochondria are closely connected by mitochondria associated ER membranes (MAMs) [35]. UGCG OE clearly affects mitochondrial respiration and therefore, we analyzed total dihydroceramide (dhCer), ceramide (Cer), glucosyleceramide (GlcCer) and lactosylceramide (LacCer) levels in ER/mitochondria fractions by LC–MS/MS. The data reveal significantly increased total dhCer (Fig. 4A), GlcCer (Fig. 4C) and LacCer levels (Fig. 4D) in NMuLi/UGCG OE cells compared to the control. Total Cer levels (Fig. 4B) are unchanged following UGCG OE. UGCG KD data verify this finding by showing significantly decreased total GlcCer and LacCer levels (S2C), whereas, total dhCer levels are unchanged and total Cer levels are increased in NMuLi/UGCG KD cells compared to control cells (S2C).

UGCG-derived glycosphingolipids accumulate in GEMs and change cell signaling pathways

To investigate whether UGCG-derived glycosphingolipids (GSL) arrive at glycosphingolipid-enriched microdomains (GEMs), we analyzed GSL levels in GEMs by LC–MS/MS. GSL fractions were obtained by saccharose density gradient centrifugation as described in Wegner et al. [46] and fraction 2 (out of 8) is verified as the GEM containing fraction by determination of cholesterol level in NMuLi/UGCG OE and control cells (Fig. 5A). Previously, we identified fraction 2 and/or 3 as GEMs containing fractions in breast cancer cells [37, 46]. Accordingly, fractions 1–5 were analyzed. In addition, our LC–MS/MS data show the highest concentration of GlcCer and LacCer in fraction 2 (out of 8 fractions) for NMuLi/EV-2 and fraction 2 and 3 (out of 8 fractions) for NMuLi/UGCG OE cells (data not shown).
Increased glucosylceramide production leads to decreased cell energy metabolism and lowered…

Our LC–MS/MS data reveals an increase of total GlcCer (fraction 1 to 8) and subsequently total LacCer (GlcCer are precursor for LacCer) concentrations in NMuLi/UGCG OE cells (Fig. 5B), which verifies UGCG OE in NMuLi cells. Furthermore, UGCG-derived GlcCer and LacCer, mainly accumulate in fraction 2 and 3 (Fig. 5C, D). Notably, NMuLi/UGCG OE cells exhibit a 12-fold increase of GlcCer concentration in fraction 2 and a sixfold increase in fraction 3 compared to control cells (Fig. 5C). LacCer levels are increased 2.5-fold in fraction 2 and 3 of NMuLi/UGCG OE cells compared to control cells (Fig. 5D). Accordingly, UGCG OE leads to sphingolipid composition changes of GEMs or to increased numbers of GEMs. Since GEMs are signaling platforms for cellular processes and proteins residing in GEMs are influenced by lipid composition, we analyzed phosphorylation of key signaling proteins. UGCG OE leads to a statistically significant decrease of phosphorylated GSK3β (P-Ser9) and AMPKα (P-Thr172) and an increase of AKT (P-Ser473) and PDKI (P-Ser241), whereas, the latter is not significant (Fig. 6A, S2D). We confirmed decreased phosphorylated GSK3β (P-Ser9), AMPKα (P-Thr172) and increased phosphorylated PDKI (P-Ser241) by Western Blot analysis (S2E, S2F). Contradictory, phosphorylated AKT (P-Ser473) was decreased when determined by Western Blot analysis (S2E, S2F).

UGCG OE decreases tumor marker expression

To get insights about the influence of UGCG OE on malignant transformation of liver cells, mRNA expression of selected tumor cell markers was analyzed by quantitative real-time-PCR (qRT-PCR). Following OE of UGCG, mRNA concentrations of the tumor markers glucose transporter type 4 (GLUT4), glucose transporter type 6 (GLUT6), fibroblast growth factor 21 (FGF21), X-box binding protein 1 (Xbp1), phosphoenolpyruvate carboxykinase 1 (PCK1), glutamate-ammonia ligase (Glul), carnitine palmitoyltransferase 1B (CPT1B), insulin-like growth factor 2 (IGF2), epithelial cell adhesion molecule (EPCAM) and cluster of differentiation 36 (CD36) are significantly decreased in NMuLi/UGCG OE cells (Fig. 6B). Interestingly, we detected increased mRNA levels of glucose transporter type 2 (GLUT2), peroxisomal
acyl-coenzyme A oxidase 1 (Acox1), peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α), alpha fetoprotein (AFP), lipocalin-2 (LCN2) and protein kinase AMP-activated catalytic subunit α 2 (Prkaa2) (Fig. 6C). GLUT2, Acox1, PGC1α, AFP, LCN2, CD36 and Prkaa2 mRNA levels are decreased in NMuLi/UGCG KD cells (S2G). In addition, we analyzed protein expression of selected liver cancer stem cell markers by flow cytometry. Following UGCG OE, protein expression of CD13+, CD133+ and CD44+ is reduced on liver cells, whereas, CD90.1+ expression is unchanged (Fig. 6D). In summary, these data reveal that UGCG OE reduces expression of tumor cell markers on normal liver cells.

UGCG OE lowers normal liver cell proliferation

Since UGCG OE in normal liver cells leads to decreased OXPHOS and glycolysis, and cell viability can be improved by treatment with an UGCG inhibitor, the direct influence of UGCG OE on cell proliferation was investigated. NMuLi/UGCG OE cells proliferate significantly less than control cells (Fig. 7A). We verified the data by performing a CyQUANT® NF Cell Proliferation Assay, which is based on a cell-permeant binding of the dye to DNA and therefore can be used for cell number determination. We could verify less NMuLi/UGCG OE proliferation compared to control cells under normal media conditions (Fig. 7B). Interestingly, low glucose media conditions increase cell numbers for both
Increased glucosylceramide production leads to decreased cell energy metabolism and lowered...

NMuLi/UGCG OE and control cells (Fig. 7B). Glutamine depletion decreases NMuLi/UGCG OE and control cell proliferation (Fig. 7B) indicating that glutamine dependency is not given following UGCG OE. Interestingly, Aurora B/AIM1 protein concentration is significantly decreased following UGCG overexpression in NMuLi cells (Fig. 7C, S2H). Aurora B/AIM1 is essential for proper cytokinesis.

Materials and methods

Cell culture

The normal murine liver cell line NMuLi (American Type Culture Collection (ATCC) CRL-1638, Manassas, Virginia, US) was cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing high glucose, L-glutamine, sodium bicarbonate, 10% fetal bovine serum (FBS) (Sigma Aldrich, St. Louis, Missouri, US) and 1% Penicillin/Streptomycin. Cells were cultured at 37 °C in an atmosphere containing 5% CO₂. 1 µg/ml puromycin (Sigma Aldrich, St. Louis, Missouri, US) was added for selection of stably transfected NMuLi/EV-2 and NMuLi/UGCG OE cells.

Cloning of UGCG and subsequent lentiviral transduction

Primers were designed with BamHI (5’) and Sal I (3’) restriction enzymes sites at the ends. UGCG was amplified by PCR and the PCR product digested and purified. Subsequently, the PCR product was ligated into purified pBabe-puro that was digested with BamHI and Sal I. As a control the pBabe-puro (Empty Vector (EV)-2) was used (NMuLi/EV-2 cells). The pBabe-puro-UGCG construct was then amplified and transfected into Platinum-E cells. Retrovirus-containing supernatant was collected 3 days later and used to infect NMuLi cells. For viral transduction, 8 × 10⁴ NMuLi cells were seeded in a 6-well. 1 ml DMEM with 10% FBS and no antibiotics was added. NMuLi cells were incubated with 4 µg/ml
polybrene and 1/10 viral supernatant for 48 h at 37 °C. Subsequently, the viral supernatant was removed, and stable cell lines were selected by puromycin treatment (1 µg/ml).

**qRT-PCR**

Quantitative real-time PCR (qRT-PCR) was performed as described previously [37]. Briefly, the RNase Mini Kit (QIAGEN, Hilden, Germany) was used to isolate total RNA. 1000 ng RNA were applied to synthesize cDNA using the Verso cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, USA). Gene-specific PCR products were quantified utilizing Fast SYBR™ Green Master Mix (Thermo Fisher Scientific, Waltham, USA) on a QuantStudio 5 Real-time PCR System (Thermo Fisher Scientific, Waltham, USA). Relative mRNA expression was calculated according to the ΔΔCt method. Relative values were normalized to cyclophilin A (or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for NMuLi/UGCG KD and control). All primers (except GAPDH), as listed in Table 1, were purchased from Sigma Aldrich (St Louis, Missouri, US). GAPDH primers were purchased from Biomers (Ulm, Germany).

**Protein concentration determination by Western blot analysis**

Cell pellets were resuspended in PhosphoSafe buffer (EMD Chemicals Inc. Billerica, USA), 2 mM dithiothreitol (DTT) (AppliChem GmbH, Darmstadt, Germany), 1 x Roche Complete (Roche, Mannheim, Germany), pH 7.4 supplemented with 1% 100 x Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific, Darmstadt, Germany). Following sonification, lysates were centrifuged (14,000 x g, 10 min, 4 °C) and protein concentration was determined by performing bicinchoninic acid (BCA) assay according to manufacturer’s protocol (Thermo Fisher Scientific, Waltham, Massachusetts, USA). 60 µg total protein extract were separated by SDS-PAGE and electro-blotted onto a nitrocellulose membrane (Amerham Protran, GE Healthcare Life Sciences, Freiburg, Germany). Verification of successful protein transfer was performed by Ponceau staining (0.5% in 1% acetic acid). Following 90 min incubation in 5% milk powder diluted in PBS with 0.1% Tween 20 (PBST) the membrane was incubated with the primary antibody anti-UGCG antibody (ab98030, Abcam, Cambridge, UK), anti-AuroraB/AIM1 antibody (3094, Cell Signaling Technology, Danvers, Massachusetts, USA) or anti-pan 14–3-3 antibody.
Increased glucosylceramide production leads to decreased cell energy metabolism and lowered…

The IRDye680 conjugated secondary antibody (LI-COR Biosciences, Bad Homburg, Germany), was used for all proteins. Fluorescence emission and densitometric analysis was performed using the Odyssey Infrared Scanner (LI-COR Biosciences, Bad Homburg, Germany) and the Image Studio Lite software (LI-COR Biosciences, Bad Homburg, Germany). For detection of mitochondrial OXPHOS complex proteins, cells were resuspended in triton buffer (120 mM NaCl, 50 mM Tris HCl (pH 8), 1% Triton X-100) and samples incubated for 5 min at 50 °C before gel was loaded. The anti-Total OXPHOS Rodent WB Antibody Cocktail (ab110413, Abcam, Cambridge, UK) was used to label OXPHOS complexes.

Measurement of mitochondrial respiration and glycolysis

The Seahorse XFe Analyzer (Agilent Technologies, Santa Clara, USA) was used to analyze both, oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in real-time. Cells were seeded and treated as described in [36]. Total cellular ATP production (JA TPproduction) was determined by calculating rates of glycolytic ATP production (JA TPGlc) and oxidative ATP production (JA TPOx) from all intracellular sources according to Mookerjee et al. and Louie et al. [27–29].

ATP level determination

For ATP level determination the ATP Bioluminescence Assay Kit CLS II (Roche, Basel, Switzerland) was used, and samples generated according to manufacturer’s protocol. Briefly, 1 × 10^7 cells were trypsinized, lysed and the luciferase-based assay performed.

Substrate competition assay

Tracer assays were performed as described in Byrne et al. [6]. Briefly, a day prior to the assay 1.5 × 10^4 cells/24-well were seeded and then incubated in Krebs Ringer Phosphate (KRP) nutrient buffer containing either D-[3–3H]-glucose, D-[14C (U)]-glucose, L[14C(U)]-glutamic acid or [1–14C]-palmitic acid. Substrate oxidation was measured capturing evolved 14CO2. For glycolysis measurements, D-[3–3H] glucose was separated from tritiated [3H]2 O by diffusion. To quantify tracer oxidation, media was acidified and 14CO2 trapped via reaction with 0.1 ml KOH before liquid scintillation spectrometry.

Analysis of mitochondrial DNA copy numbers per cell

To compare the nuclear to mitochondrial DNA ratio, the NovaQUANT Human Mitochondrial to Nuclear DNA Ratio Kit (Merck KGaA, Darmstadt, Germany) and SYBR select
Master Mix (Thermo Fisher Scientific, Waltham, USA) were used. The qRT-PCR based kit contains primer pairs targeting two mitochondrial (ND1 and ND6) and two nuclear genes (BECN1 and NEB). By calculating ratios of the Ct values of BECN1/ND1 and NEB/ND6, the mtDNA copy number per cell was determined. DNA was isolated using KAPA Express Extract Kit (Kapa Biosystems, Wilmington, USA).

**Comparison of mitochondrial mass using NAO**

Cells were seeded in 6 cm dishes and treated with 100 nM nonyl acridine orange (NAO). Cells were washed, harvested by trypsin and pelletized. Mitochondrial staining of 100,000 cells per sample was analyzed via FITC channel with the BD FACs Canto II flow cytometer and the BD FACSDiva software (BD Biosciences, Franklin Lakes, USA). Data were evaluated using FlowJo software (FlowJo LLC, Ashland, USA).

**Quantification of mitochondrial superoxide**

0.5 × 10^4 cells/96-well were seeded and incubated with 5 μM Red mitochondrial superoxide indicator for live-cell imaging (MitoSOX) (Thermo Fisher Scientific, Waltham, USA) for 30 min at 37 °C. Following a three-time washing step with PBS, fluorescence was detected by the EnSight Multimode Plate reader (PerkinElmer, Waltham, Massachusetts, US) with excitation at 510 nm and emission at 590 nm. The values are background corrected.

**Determination of total ROS levels**

Total reactive oxygen species (ROS) levels determination was performed using 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester (CMH2DCFDA) (Invitrogen, Carlsbad, USA) according to manufacturer’s protocol. CM-H2DCFDA diffuses passively into cells where the acetate groups are cleaved by esterases and the thiol-reactive chloromethyl group reacts with GSH and other thiols. Subsequent oxidation leads to a fluorescent adduct, which is trapped inside the cell and is measured at Ex/Em ~ 492–495/517–527 nm.

**Determination of cell viability**

To determine cell viability, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed. 1.2 × 10^4 cells/96-well were seeded and stimulated for 24 h with 0, 5 and 25 μM PDMP. 20 μl MTT reagent (5 mg/ml in 1 × PBS) was added, and plates incubated for three hours at 37 °C. Subsequently, media was aspirated and 80 μl MTT solvent (4 mM HCl, 0.1% NP-40, isopropanol) added. Following a 15-min incubation time, absorbance (590/620 nm) was measured on the EnSight Multimode Plate reader (PerkinElmer, Waltham, Massachusetts, US). Data are normalized to protein concentration.

**Sphingolipid level analysis of endoplasmic reticulum (ER)/mitochondria fractions**

To analyze the lipid composition of the endoplasmic reticulum (ER)/mitochondria fractions, mitochondria from 1.5 × 10^7 freshly harvested cells were isolated according to the manufacturer’s protocol using the Qproteome Mitochondria Isolation Kit (Cat. no. 37612, QIAGEN, Hilden, Germany). Sphingolipid concentrations of isolated ER/ mitochondria fractions were determined by liquid chromatography tandem mass spectrometry (LC–MS/MS) as described previously [36]. Data are normalized to protein concentration.

**Isolation and identification of GEMs**

Glycosphingolipid-enriched microdomains (GEMs) were isolated and identified by determination of the cholesterol level and glycosphingolipid (GSL) levels as previously described in [46]. Briefly, cells were harvested, processed and sonified in MES buffer and ultra-centrifuged in a saccharose density gradient. Eight fractions were isolated and purified from saccharose and the GEM containing fractions were identified. GlcCer and LacCer concentrations in fraction 1 to 8 were analyzed by LC–MS/MS as previously described in [46].

**Detection of intracellular-induced signaling pathways**

For analysis of activated signaling pathways in NMuLi cells, the C-Series AKT Pathway Phosphorylation Array C1 (RayBiotech, Norcross, Georgia, US) was used. This antibody array detects several phosphorylated signaling proteins. The assay was performed according to the manufacturer’s protocol.

**HCC stem cell marker detection**

For analysis of CD13, CD133, CD44 and CD90.1 expression, samples were acquired with a LSRII/Fortessa flow cytometer (BD Biosciences, Heidelberg, Germany) and mean fluorescence intensity (MFI) was determined using FlowJo software 7.6.1 (Treestar, Ashland, OR, USA). All antibodies and secondary reagents were titrated to determine optimal concentrations. The instrument calibration was controlled daily using Cytometer Setup and Tracking beads (BD Bioscience, Franklin Lakes, New Jersey, US). For staining of murine NMuLi UGCG OE and control cells,
cell suspensions were blocked with Fc Receptor Binding Inhibitor (Miltenyi Biotec, Bergisch Gladbach, Germany) for 10 min on ice and stained with anti-CD133-PerCP-eFluor710 (eBioscience, San Diego, California, US), anti-CD44-BV510 (BD Bioscience, Franklin Lakes, New Jersey, US), anti-CD90.1-PE (eBioscience, San Diego, California, US) or anti-CD13-BV421 (BD Bioscience, Franklin Lakes, New Jersey, US) for 10 min on ice.

**Cell proliferation assays**

1.2 × 10⁴ cells/24-well were seeded in media (day 0). Cells were harvested with trypsin on day 4 and cell number determined by using a Neubauer counting chamber. The second method, which was used to determine cell proliferation is the CyQUANT™ NF cell proliferation assay (Thermo Fisher Scientific, Waltham, USA). The assay was performed according to manufacturer’s protocol. Briefly, 1.2 × 10⁴ cells/96-well were seeded in control media (DMEM, phenol-red free, 1 × sodium bicarbonate solution, 1% Penicillin/Streptomycin, 10% FBS, 1.139 g/l-glucose, 1% GlutaMAX), without glucose supplementation or in low glucose media (0.25 g/l). On day three, growth media was removed and replaced by 100 μl/well of 1× dye binding solution containing 1 × HBSS buffer, 1:500 CyQUANT® NF dye reagent and 1:500 CyQUANT® delivery reagent. Plate was covered and incubated for 60 min at 37 °C. Subsequently, fluorescence intensity was measured at Ex/Em ~ 485/530 nm on the EnSight Multimode Plate reader (PerkinElmer, Waltham, Massachusetts, US). Data are normalized to protein concentration.

**Statistical analysis**

Statistical analysis was performed with GraphPad Prism 8 software. Data are presented as mean ± standard error of the mean (SEM). Significant differences in means between two groups were assessed by unpaired t test with Welch’s correction and by one-way ANOVA (Tukey’s multiple comparisons test) for more than two groups. Statistical outliers were identified using a ROUT outlier test with Q = 1%.

**Discussion**

**OXPHOS affected by UGCG**

Following UGCG OE in NMuLi cells, we detected lowered basal mitochondrial respiration, lowered ATP levels and lowered cell proliferation. These changes are not ascribable to altered mitochondrial mass. Presumably, the accumulation of UGCCG-derived GlcCer and LacCer in ER/mitochondria fractions induces mitochondrial superoxide and subsequently leads to the described effects in the liver cells. Our normal liver cell data are in line with studies in cancer cells showing GSL related mitochondrial dysfunction (reviewed in [35]). Although, we previously showed that in breast cancer cells, accumulation of GlcCer in ER/mitochondria fractions leads to increased mitochondrial respiration [36] and increased cell proliferation [46]. It is likely that UGCG/GlcCer have different roles in normal cells compared to cancer cells and are regulated differently. Furthermore, we detected increased dihydroceramide (dhCer) levels in ER/mitochondria fractions of UGCG OE liver cells. Interestingly, in UGCG overexpressing breast cancer cells, no changes in dhCer concentrations in ER/mitochondria fractions were detected [36]. However, dihydroceramide desaturase 1 (DEGS1) introduces a 4,5-trans-double bond into dhCer and thereby generates ceramide (Cer). Following UGCG OE in liver cells, DEGS1 mRNA expression is reduced, while the effect is not significant (data not shown). Increased DEGS1 mRNA expression might be responsible for the detected dhCer accumulation in NMuLi/UGCG OE cells. Siddique et al. showed that specifically dhCer increase impairs ATP production [39], which might be the reason for decreased ATP production following UGCG OE in NMuLi cells. No significant differences of 5,5,6,6′-tetraarylbenzimidazoyl-carbocyanine iodide (JC-1) aggregate to monomer ratio was detected by flow cytometry, which shows that UGCG by itself does not influence mitochondrial depolarization (S2I). However, Lachkar et al. reviewed that a sphingosine kinase 2 inhibitor targets DEGS1 activity, leading to increased dhCer concentrations in prostate cancer cells. This results in decreased cell size and cell proliferation, without affecting apoptosis or autophagic cell death (reviewed in [22]). In addition, changed dhCer content results in changed membrane fluidity (reviewed in [22]). Changes of lipid composition of biological membranes affects protein activity and therefore regulates cellular processes (reviewed in [10]). Furthermore, following DEGS1 ablation, autophagy is induced in an AMPK-dependent manner [39]. This is contradictory to our data, because we detected less phosphorylated, respectively less active AMPKα. In future experiments autophagy induction analysis following UGCG OE in liver cells should be included.

**Glycolysis affected by UGCG**

Decreased ATP levels in NMuLi/UGCG OE cells suggest increased adenosine monophosphate (AMP) levels. Usually, increased concentrations of AMP during mitochondrial dysfunction activate the energy sensor AMPK by binding to the γ-subunit, which leads to phosphorylation of Thr172 (reviewed in [49]). Subsequently, AMPKα is activated, which leads to induction of energy producing pathways.
such as glycolysis [49]. Decreased levels of phosphorylated AMPKα (P-Thr172) following UGCG OE in NMuLi cells could be the reason for lowered glycolysis in NMuLi/UGCG OE cells. mRNA expression of the catalytic subunit (α-subunit, Prkaa2) of AMPK might be increased for compensatory reasons. Interestingly, mice without hepatic expression of acetyl-CoA carboxylase (ACC) develop liver tumors [30]. ACC catalyzes the first step of de novo lipogenesis in the cytosol. Acetyl-CoA is converted into malonyl-CoA, which serves as substrate for lipid synthesis. Ishibashi et al. showed a connection between UGCG and ACC in murine fibroblasts [20]. AMPK-induced phosphorylation and subsequent inhibition of ACC leads to decreased UGCG activity and accordingly lowered GlcCer levels. Inhibition of ACC lowers the production of malonyl-CoA, which is necessary for fatty acid synthesis [19]. This arises the question whether UGCG and ACC are connected in the context of liver tumor development. We analyzed ACC1 and ACC2 mRNA and protein expression but could not detect a clear trend (data not shown). Malonyl-CoA inhibits CPT1B (rate controlling enzyme of β-oxidation), which we detected to be less expressed in NMuLi/UGCG OE cells. Reduced CPT1B indicates reduced β-oxidation, but to clearly state be less expressed in NMuLi/UGCG OE cells. Decreased controlling enzyme of β-oxidation, which we detected to trend (data not shown). Malonyl-CoA inhibits CPT1B (rate controlling enzyme of β-oxidation), which we detected to be less expressed in NMuLi/UGCG OE cells. Reduced CPT1B indicates reduced β-oxidation, but to clearly state to what extend β-oxidation contributes to CO₂ formation in NMuLi/UGCG OE and control cells further studies are needed. However, under various cellular stresses, induced AMPK activates AKT (P-Ser473) [18]. Interestingly, we obtained contradictory data in regards to AKT (P-Ser473) activation. AKT might be activated via mTOR (reviewed in [52]). We analyzed mRNA expression of mechanistic target of rapamycin (mTOR) and its regulating proteins regulatory-associated protein of mTOR (RPTOR) (rapamycin complex 1 (mTORC1) activity regulation) and DEP-domain containing mTOR-interacting protein (DEPTOR). mRNA levels of all three genes are not affected by UGCG OE in liver cells (data not shown), meaning AKT pathway activation seems not be induced by the mTOR signaling pathway. However, activated AKT (P-Ser473) usually phosphorylates GSK3β at serine 9, thereby causing inactivation of the protein (reviewed in [3]). Interestingly, we detected less GSK3β (P-Ser9), which means GSK3β is activated following UGCG OE in liver cells compared to control cells. Controversial data exist regarding GSK3β and its involvement in cell proliferation (reviewed in [7]). In NMuLi/UGCG OE cells, GSK3β decreases cell proliferation, which we showed with two proliferation assays. We detected slightly increased PDK1 (P-Ser241) levels following UGCG OE and PDK1 is constitutively active when phosphorylated at P-Ser241 [8]. PDK1, the master regulator of proliferative signaling, activates AKT [47], which we detected in NMuLi/UGCG OE cells by using the C-Series AKT Pathway Phosphorylation Array C1. Activation of PDK1 could be a rescue attempt of the cell to boost cell proliferation. However, UGCG inhibitor EtDO-P4 treatment clearly improves mitochondrial respiration and glycolysis of NMuLi/UGCG OE cells. Interestingly, EtDO-P4 decreases ATP production and glycolytic capacity of control liver cells. Also, EtDO-P4 increases maximal respiration and basal ECAR in NMuLi/EV-2 cells. EtDO-P4 might affect these parameters in the control cells by blocking UGCG, which is expressed at basal level in control cells. This shows the complexity of the sphingolipid metabolism and how small changes lead to profound alterations of cellular processes (reviewed in [4]). We hypothesize that control cells following EtDO-P4 treatment are forced to adapt to changed sphingolipid levels. This hypothesis is supported by our NMuLi/UGCG KD data, which show no effect of EtDO-P4 treatment on mitochondrial respiration and glycolysis. In addition, the EtDO-P4 effect is much smaller in NMuLi/EV-2 cells and NMuLi/UGCG OE cells are clearly rescued by EtDO-P4 treatment.

Expression of tumor markers affected by UGCG

Here, we show that UGCG OE leads in liver cells to GlcCer and LacCer accumulation in GEMs and therefore changes signaling cascades in the cell. We detected reduced expression levels of EPCAM, CD13, CD133, CD90.1 and CD44, which are known liver cancer stem cell markers (LCSC) (reviewed in [44]). Furthermore, the pro-cancerous markers GLUT4 [15], GLUT6 (reviewed in [5], FGF21 [50], Xbp1 [48], PCK1 [38], Glul [26], CPT1B [1], IGF2 (reviewed in [48], PCK1 [38], Glul [26]) are increased in HCC, which led us to hypothesize that this might be either a compensatory effect or an early-onset of pro-cancerous processes. PGC1α has an essential role in the control of hepatic gluconeogenesis (reviewed in [24]), which indicates that PGC1α is upregulated to allow for sufficient energy supply for NMuLi/UGCG OE cells, which exhibit decreased OXPHOS and glycolysis. Alpha fetoprotein (AFP), together with des-γ-carboxy prothrombin (DCP) has been shown to be beneficial for serological diagnosis of HCC [12]. Since we only analyzed AFP in NMuLi cells, DCP expression must be investigated in the future. The role of LCN2 in epithelial cancers is double-edged (reviewed in [51]). Santiago-Sánchez et al. recently discussed the role of LCN2 in a review. The majority of studies suggest LCN2 as a tumor promoter, while some studies show that increased
LCN2 levels correlate with reduced tumor growth in certain cancer types (reviewed in [34]). However, it has been shown that Prkaa2 sensitizes HCC to several drugs (reviewed in Yildiz 2018*), but the precise molecular mechanisms are unknown.

**Proliferation affected by UGCG**

Contradictory to our results is a study from Li et al., which showed inhibited HL-7702 (human hepatocytes) cell proliferation following UGCG (siRNA) depletion [23]. We were able to show that proliferation is impaired following UGCG OE in NMuLi cells by performing two proliferation assays. Furthermore, cell viability (MTT assay) is reduced (not statistically significant) and statistically significant increased following UGCG inhibition with PDMP in NMuLi/UGCG OE cells. Given the importance of cytokinesis for cell viability, it is interesting that we detected reduced Aurora B/AIM1 protein concentration. Aurora B/AIM1 is essential for proper cytokinesis [17]. Aurora B/AIM1 expression reaches its maximum at the G2/M cycle transition. Possibly, UGCG overexpression leads to increased degradation of Aurora B/AIM1. However, no statistically significant differences between tumor necrosis factor α (TNFα) and cytochrome C release following UGCG KD were detected by Li et al. [23]. B-cell lymphoma 2 (Bcl-2) mRNA expression is reduced, whereas, Bcl-2-associated X protein (Bax) and caspase-3 expression is induced, which indicates induction of apoptotic processes [23]. We were able to lower UGCG mRNA expression to 30% compared to control cells. In the study of Li et al., human hepatocytes were used and UGCG expression is lowered to 40%, which might be the reason for the differences in the study outcome. Also, we have not checked the effect of UGCG on apoptotic processes in normal liver cells. Unexpectedly, low glucose media conditions increase cell numbers for both NMuLi/UGCG OE and control cells. One explanation is that UGCG is less active since less glucose is available and thereby UGCG generates less GlcCer. Accordingly, UGCG/GlcCer do not induce the effects described by Li et al. [23] in NMuLi cells. This must be investigated in further studies.

**Conclusion**

In this study we were able to show that UDP-glucose ceramide glucosyltransferase (UGCG) overexpression (OE) decreases mitochondrial respiration and glycolysis in normal murine liver cells. Furthermore, expression of tumor markers is lowered and UGCG-derived glucosylceramide (GlcCer) and lactosylceramide (LacCer) accumulate in glycosphin-golipid-enriched microdomains (GEMs). In endoplasmic reticulum (ER)/mitochondria fractions an accumulation of GlcCer, LacCer and dihydroceramide (dhCer) was detected. This results in decreased cell proliferation (graphic abstract). Our data show that OE of UGCG per se does not induce pro-cancerous processes in normal liver cells.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00018-021-03958-9.

**Acknowledgements** We would like to thank Simone Schaubeck (Dr. Manuel Kaulich, Institute of Biochemistry II, University Clinic Frankfurt am Main) for generating the virus for UGCG KD in murine cells.

**Author contributions** MSW designed the study and performed qRT-PCR, OCR and ECAR analysis, ATP level determination, Western blot analysis, substrate competition assays and proliferation assays. NS performed UGCG KD in NMuLi cells, isolated the GEMs, performed Western blots analysis and the antibody-based assay for protein phosphorylation. EMO cultured NMuLi cells and revised the manuscript. ST and RG participated in the discussion of the results of the study. KLH supervised and wrote parts the manuscript.

**Funding** Open Access funding enabled and organized by Projekt DEAL. This work was funded by the Deutsche Forschungsgemeinschaft (WE 5825/2-1 and CRC 1039, TP B04, B06, Z01). We would like to thank Simone Schaubeck (Dr. Manuel Kaulich, Institute of Biochemistry II, University Clinic Frankfurt am Main) for generating the virus for UGCG KD in murine cells.

**Availability of data and material** Not applicable.

**Data availability** All data generated or analysed during this study are included in this published article (and its supplementary information files).

**Code availability** Not applicable.

**Declarations**

**Conflict of interest** We declare that the authors have no competing interests that might be perceived to influence the content of this manuscript.

**Ethics approval** Not applicable.

**Consent to participate** Not applicable.

**Consent for publication** Not applicable.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Abudurexiti M, Zhu W, Wang Y, Wang J, Xu W, Huang Y, Zhu Y, Shi G, Zhang H, Zhu Y, Shen Y, Dai B, Wan F, Lin G, Ye D (2020) Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer. Prostate 80:950–961

2. Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H, Iyo S, Kubota K, Shimada M, Utsumiyo T, Hirooka M, Hiasa Y, Toyoki Y, Hakamada K, Yasui K, Kumada T, Toyoda H, Sato S, Hisai H, Kuzuya T, Tsuchiya K, Izumi N, Arii S, Nishio K, Kudo M (2013) FGFR3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 57:1407–1415

3. Beaulieu JM, Del’Guidice T, Sotnikova TD, Lemasson M, Gainetdinov RR (2011) Beyond cAMP: the regulation of Akt and GSK3 by dopamine receptors. Front Mol Neurosci 4:38

4. Breslow DK, Weissman JS (2010) Membranes in balance: mechanisms of sphingolipid homeostasis. Mol Cell 40:267–279

5. Byrne FL, Olzomer EM, Brink R, Hoehn KL (2018) Knockout of glucose transporter GLUT6 has minimal effects on whole body metabolic physiology in mice. Am J Physiol Endocrinol Metab 315:E286–E293

6. Byrne FL, Olzomer EM, Marriott GR, Quek LE, Kateh A, Su J, Nelson ME, Hart-Smith G, Larance M, Sebeski VF, Cuff J, Martyn GE, Childress CJ, Axelopoulos SJ, Poon IK, Faux MC, Burgess AW, Reid G, McClarron JA, Santos WL, Quinlan KG, Turner N, Fazakerley DJ, Kumar N, Hoehn KL (2020) Phenotypic screen for oxygen consumption rate identifies an anticancer naphthyphenone that induces mitochondrial oxidative stress. Redox Biol 28:101374

7. Cai G, Wang J, Xin X, Ke Z, Luo J (2007) Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells. Int J Oncol 31:657–662

8. Casamayor A, Morrice NA, Alessi DR (1999) Phosphorylation in vivo. Biochem J 342(Pt 2):287–292

9. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404

10. Conrard L, Tytce D (2019) Regulation of membrane calcium transport proteins by the surrounding lipid environment. Bio-molecules 9:513

11. Doneda D, Netto CB, Moulin CC, Schwartz IV (2013) Effects of conrard l, tyteca d, lemasson m, gainetdinov rr (2011) beyond cAMP: the regulation of Akt and GSK3 by dopamine receptors. Front Mol Neurosci 4:38

12. Ertle JM, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, Doneda D, Netto CB, Moulin CC, Schwartz IV (2013) Effects of...
Increased glucosylceramide production leads to decreased cell energy metabolism and lowered...

33. Regenboog M, van Dussen L, Verheij J, Weinreb NJ, Santos A, vom Dahl S, Hüssinger D, Müller MN, Canbay A, Rigoldi M, Piperno A, Dinur T, Zimran A, Mistry PK, Salah KY, Belmatoug N, Kuter DJ, Hollak CEM (2018) Hepatocellular carcinoma in Gaucher disease: an international case series. J Inherit Metab Dis 41:819–827

34. Santiago-Sánchez GS, Pita-Grisanti V, Quiñones-Díaz B, Gumper K, Cruz-Monserrate Z, Vivas-Mejia PE (2020) Biological functions and therapeutic potential of lipocalin 2 in cancer. Int J Mol Sci 21:e4365

35. Schömel N, Geisslinger G, Wegner MS (2020) Influence of glucosylglucosinolipids on cancer cell energy metabolism. Prog Lipid Res 79:101050

36. Schömel N, Gruber L, Alexopoulos SJ, Trautmann S, Olzomer EM, Byrne FL, Hoehn KL, Gurke R, Thomas D, Ferreirós N, Geisslinger G, Wegner MS (2020) UGCG overexpression leads to increased glycolysis and increased oxidative phosphorylation of breast cancer cells. Sci Rep 10:8182

37. Schömel N, Hancock SE, Gruber L, Olzomer EM, Byrne FL, Shah D, Hoehn KL, Turner N, Grösch S, Geisslinger G, Wegner MS (2019) UGCG influences glutamine metabolism of breast cancer cells. Sci Rep 9:15665

38. Shi L, An S, Liu Y, Liu J, Wang F (2020) PCK1 regulates glycolysis and tumor progression in clear cell renal cell carcinoma through LDHA. Onco Targets Ther 13:2613–2627

39. Siddique MM, Li Y, Wang L, Ching J, Mal M, Ilkayeva O, Wu YJ, Bay BH, Summers SA (2013) Ablation of dihydroceramide desaturase 1, a therapeutic target for the treatment of metabolic diseases, simultaneously stimulates anabolic and catabolic signaling. Mol Cell Biol 33:2353–2369

40. Stefanovic M, Tutusaus A, Martinez-Nieto GA, Bárcena C, de Gregorio E, Moutinho C, Barbaro-Camps E, Villanueva A, Colell A, Mari M, García-Ruiz C, Fernandez-Checa JC, Morales A (2016) Targeting glucosylceramide synthase upregulation reverts saraefinb resistance in experimental hepatocellular carcinoma. Oncotarget 7:8253–8267

41. Tenen DG, Chai L, Tan JL (2021) Metabolic alterations and vulnerabilities in hepatocellular carcinoma. Gastroenterol Rep (Oxf) 9:1–13

42. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O’Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A (2010) Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 28:3994–4005

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.